All In Biotech

Drug Trial Radar · NCT00671918

Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma

A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping

Last checked: Nov 20, 2026Latest source record: Jun 17, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

186

Actual

Start

Apr 2008

Primary completion

Jun 2009

Study completion Jul 2009

Sponsor

Lead sponsor
Navidea BiopharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 5, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Data from this pivotal clinical trial will be used to support a marketing application (i.e., NDA) for Navidea's Lymphoseek for use in intraoperative localization of lymph tissue (nodes) in the lymphatic pathway draining the primary site of a tumor.

Conditions

  • Breast Cancer
  • Melanoma

Interventions

  • LymphoseekDrug

    Breast Cancer: Intradermal admin of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site OR periareolar administration of Lymphoseek: Inject 0.2-.04 mL in multiple divided doses at the margin of the areola OR subareolar administration of Lymphoseek: Inject 0.2-0.4 in multiple divided injections or a single injection in subareolar area as a subcutaneous injection OR peritumor administration of Lymphoseek: Inject 2.0-4.0 mL in multiple divided injections, intraparenchemally surrounding the tumor or biopsy cavity. For melanoma pts intradermal administration of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Concordance of Blue Dye and LymphoseekTime frame: Surgery after injections of Lymphoseek and blue dye

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Barbara Michna, M.D

    Alexander City, Alabama

  • Helen Krontiras, M.D.

    Birmingham, Alabama

  • Anne Wallace, M.D.

    La Jolla, California

  • Ken Deck, M.D.

    Laguna Hills, California

  • Steve Martinez, M.D.

    Sacramento, California

  • Mark Faries, M.D.

    Santa Monica, California

  • Eli Avisar, M.D.

    Miami, Florida

  • Charles Cox, M.D.

    Tampa, Florida

  • Vernon Sondak, M.D.

    Tampa, Florida

  • Julian Kim, M.D.

    Cleveland, Ohio

  • Bruce Averbook, M.D

    Cleveland, Ohio

  • Stephen Povoski, M.D.

    Columbus, Ohio

  • Thomas Frazier, M.D.

    Bryn Mawr, Pennsylvania

  • Ned Carp, M.D.

    Philadelphia, Pennsylvania

  • Schlomo Schneebaum, M.D.

    Tel Aviv, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.